Trials & Treatments Digest Archive
Lupus Making Headlines Indicates New Level of Promise…and Hope
ImmuPharma in licensing talks for lupus drug
Good news! Investigational Lupuzor gets go-ahead to start a Phase III trial from U.S., European and Japanese regulatory authorities.
Repeat Rituximab Works in Treatment-Resistant Lupus
Imaging Shows Value of Statins in Lupus
Arthritis Research & Therapy Abstract
GSK, HGS lupus drug wins green light in Europe
Nature Medicine: LRI President Margaret Dowd says FDA’s recent approval of BenlystaTM gives industry the confidence to move forward on other lupus therapies.
Thursday, April 7, 2011
After half-century's wait, approval paves path for new lupus drug.
Nat Med. 2011 Apr;17(4):400.
Benlysta Success Paves Path for Testing Other Drugs in Lupus
Commentary from Dr. Daniel J. Wallace of the David Geffen School of Medicine at UCLA, and a founder of Lupus LA. Dr. Wallace was a top enroller of the two clinical trials of Benlysta.
First lupus drug in half a century approved.
FDA APPROVES BENLYSTA® FOR LUPUS IN BREAKTHROUGH FOR MILLIONS OF SUFFERERS
Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials.
Lupus. 2011 Mar 7.
Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study.
Arthritis Res Ther. 2011 Mar 1;13(2):R36.
Targeted therapies in systemic lupus erythematosus: successes, failures and future.
Hahn BH.
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i64-i66. Review.
BAFF inhibition: A new class of drugs for the treatment of autoimmunity.
Exp Cell Res. 2011 Feb 17.
Treatment of systemic lupus erythematosus with epratuzumab.
Br J Clin Pharmacol. 2011 Feb;71(2):175-82. doi: 10.1111/j.1365-2125.2010.03767.x.
The genetics of systemic lupus erythematosus and implications for targeted therapy.
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i37-43. Review.
Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside.
Curr Opin Rheumatol. 2011 May;23(3):305-10.
Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis.
J Investig Med. 2011 Feb;59(2):246-58.
Type I interferon in organ-targeted autoimmune and inflammatory diseases.
Arthritis Res Ther. 2010;12 Suppl 1:S5. Epub 2010 Aug 25.
Antiphospholipid Syndrome Clinical Research Task Force report.
Lupus. 2011 Feb;20(2):219-24.
Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010.
Lupus. 2011 Feb;20(2):158-64.
Novel treatments for systemic lupus erythematosus.
Curr Opin Investig Drugs. 2010 Nov;11(11):1256-64.
International consensus for a definition of disease flare in lupus.
Lupus. 2010 Dec 10.
UCB Announces Start of Phase III Program with Epratuzumab for Patients with Moderate to Severe SLE
Mitigate Risk and Increase Success of Lupus Clinical Trials
Key LRI Conference Design Strategies Reach 11,500 Rheumatologists Residents, Nurse Practitioners, and more…
Epratuzumab Phase IIb Study Shows Positive Effect in Moderate to Severe S.L.E.
November 9, 2010
Advances in drug therapy for systemic lupus erythematosus.
BMC Med. 2010 Nov 29;8:77. Review.
Treatment of lupus nephritis.
Expert Rev Clin Immunol. 2010 Nov;6(6):901-11.
Lupus Research Institute Hails Results of CellCept® Trial in People with Lupus Kidney Disease
Persistence pays off as phase III study points to possible new treatment for this often deadly lupus complication
CellCept® Has Positive Results in Phase III Lupus Nephritis Trial
Maintenance phase of Aspreva Lupus Management Study (ALMS) successfully achieves primary endpoint
Target therapies in systemic lupus erythematosus: current state of the art.
Mini Rev Med Chem. 2010 Sep;10(10):956-65. Review.
News on Possible Drug for Lupus—Benlysta™
Human Genome Sciences (HGS) and GlaxoSmithKline Report Topline Results of 76-Week, Phase 3 Study
Study in Sisters of Women with SLE
Enrollment begins nationwide
New and emerging treatment approaches to lupus.
Biologics. 2010 Sep 13;4:263-71.
A new tool for detection of type I interferon activation in systemic lupus erythematosus.
Arthritis Res Ther. 2010;12(4):138. Epub 2010 Aug 26.
Cutaneous lupus erythematosus: Update of therapeutic options Part II.
J Am Acad Dermatol. 2010 Aug 25. [Epub ahead of print]
Biological therapy for lupus nephritis-tribulations and trials.
Nat Rev Rheumatol. 2010 Sep;6(9):547-52. Epub 2010 Jul 20.
|
Ocrelizumab Trial Halted
Biogen, Roche report safety risks outweigh benefits
The Lupus Drug Gold Mine
After decades of dead ends scientists find new treatments
Idera moves autoimmune disease treatment to Phase 1 trials
More Good News for Lupus at the American College of Rheumatology Meeting
Lupus Research Institute Encouraged by Phase 2 Trial Results of Experimental Drug Epratuzumab
UPDATE 2-UCB, Immunomedics drug shows promise for lupus
Lupus drug passes key test, researchers say
Lupus Research Institute Highly Encouraged by Benlysta™ Trial Results
First Phase 3 Lupus Drug Trial in Decades to Show Effectiveness
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for Benlysta™
Human Genome Seeks To Surprise Doubters With Lupus-Drug Data
HGS Hoping to Survive Final Test of Lupus Drug
Human Genome's Lupus Drug Shows Success in Trials; Shares Jump
Human Genome Sciences - Racing To Cure Lupus
UM Spinoff Lycera To Receive $36 Million Financing
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Best Selling Cancer Drug Could Become First New Treatment for Lupus in 50 Years
Rituximab Reduces Kidney Inflammation in Patients with Lupus
Clinical trial is halted for lupus drug Riquent
Cephalon pays $30M to license lupus drug
Human Genome Sciences Reports Substantial Progress Toward Commercialization